Logo

Incyte and Novartis Publish Results of Jakafi (ruxolitinib) in P-III REACH3 Study to Treat Chronic Graft-Versus-Host Disease in NEJM

Share this
Incyte and Novartis Publish Results of Jakafi (ruxolitinib) in P-III REACH3 Study to Treat Chronic Graft-Versus-Host Disease in NEJM

Incyte and Novartis Publish Results of Jakafi (ruxolitinib) in P-III REACH3 Study to Treat Chronic Graft-Versus-Host Disease in NEJM

Shots:

  • The P-III REACH3 study involves the safety & efficacy of ruxolitinib vs BAT in patients with steroid-refractory chronic GVHD
  • The study showed improvements in 1EPs i.e ORR (49.7% vs 25.6%) & BOR (76.4% vs 60.4%) @24wks. & also showed the improvements in 2EPs i.e patients achieved longer FFS than BAT- m-FFS (not reached vs. 5.7mos.); improvements in self-reported symptoms (24.2% vs 11.0%)- no new safety signals were observed
  • The new subgroup analysis showed higher ORR for Jakavi-treated patients regardless of individual organs involved at baseline. Regulatory submissions are currently ongoing for acute & chronic GvHD outside the US

  Ref: Novartis | Image: Novartis 

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions